VISITECT CD4
- UID
- IMP/IVD/2018/000005_ec00bb92ff0d4245dc343c83537bc3f8_e1ea23b093607e2b6d5169348883c762
- Device class
- Class C
- Brand name
- Pathozyme® Ovarian Cancer Antigen Ag 125 ELISA
- License holder
- Omega DX (Asia) Private Limited
- Approving authority
- CDSCO
- Product information
- The VISTECT CD4 Rapid Test is a semi-quantitative assay for the estimation of CD4 protein on the surface of CD4+ T cells in human whole bood to indicate whether the level is above or below 350 cells/uL within pre-diagnosed HIV patients
VISITECT CD4 is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2018/000005_ec00bb92ff0d4245dc343c83537bc3f8_e1ea23b093607e2b6d5169348883c762. This device is marketed under the brand name Pathozyme® Ovarian Cancer Antigen Ag 125 ELISA. The license holder is Omega DX (Asia) Private Limited, and it is classified as Device Class Class C. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.